,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Mr. J. Scott Wolchko', 'age': 52, 'title': 'Founder, CEO, Pres & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 645000, 'exercisedValue': 3854968, 'unexercisedValue': 1599920}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
1,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Mr. Edward J. Dulac III', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 0, 'unexercisedValue': 0}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
2,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Ms. Cindy R. Tahl', 'age': 49, 'title': 'Gen. Counsel & Corp. Sec.', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 3890153, 'unexercisedValue': 656415}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
3,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Dr. Bahram  Valamehr Ph.D.', 'age': 45, 'title': 'Chief R&D Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 1390425, 'unexercisedValue': 939510}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
4,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Mr. Jim  Beitel M.B.A.', 'title': 'Sr. VP of Corp. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
5,12278 Scripps Summit Drive,San Diego,CA,92131,United States,858 875 1800,https://www.fatetherapeutics.com,Biotechnology,Healthcare,"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.",551,"{'maxAge': 1, 'name': 'Dr. Jerome  Bressi Ph.D.', 'title': 'Sr. VP of Regulatory & Quality', 'exercisedValue': 0, 'unexercisedValue': 0}",8,5,7,8,7,1693526400,1672444800,86400,4,2.217,2.207,2.207,2.207,2.217,2.207,2.207,2.207,0.0,1.465076,-0.8328302,75,75,48,7,7,2.019,2.042,140000,130000,217527216,2.207,25.125,1.8241276,3.15354,5.8388,0.0,0.0,EUR,-53071088,-1.7741001,83811578,98562400,0.014529999,1.16303,4.443,0.49673647,1672444800,1703980800,1688083200,-211562000,-1.98,-2.65,2.62,-0.445,0.236,FRA,EQUITY,F6T.F,F6T.F,"FATE THERAPEUTICS DL-,001","Fate Therapeutics, Inc.",1380780000,Europe/Berlin,CEST,7200000,2.207,145.0,71.0,109.83,114.0,1.9,buy,18,377935008,3.834,-225275008,106348000,8.545,8.776,119250000,24.294,1.221,-0.21731001,-0.41554,-224154000,-114285376,-187788992,-0.95,-1.29361,-1.8891001,-2.02907,USD,
